Dabigatran Etexilate Mesylate is used for preventing and treating blood clots. It was first introduced by Boehringer Ingelheim Pharmaceuticals Inc in its drug Pradaxa on Oct 19, 2010. 10 different companies have introduced drugs containing Dabigatran Etexilate Mesylate.

Dabigatran Etexilate Mesylate Patents

Given below is the list of patents protecting Dabigatran Etexilate Mesylate, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Pradaxa	US9034822 (Pediatric)	Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds	Jul 20, 2031	Boehringer Ingelheim
Pradaxa	US9034822	Methods of using antibodies during anticoagulant therapy of dabigatran and/or related compounds	Jan 20, 2031	Boehringer Ingelheim
Pradaxa	US7866474 (Pediatric)	Film container	Mar 02, 2028	Boehringer Ingelheim
Pradaxa	US7866474	Film container	Aug 31, 2027	Boehringer Ingelheim
Pradaxa	US7932273 (Pediatric)	3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament	Mar 07, 2026	Boehringer Ingelheim
Pradaxa	US7932273	3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl) phenylamino]methyl}-1-methyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as a medicament	Sep 07, 2025	Boehringer Ingelheim
Pradaxa	US9925174 (Pediatric)	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof	Dec 14, 2023 (Expired)	Boehringer Ingelheim
Pradaxa	US9925174	Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonyl-amino-imino-methyl)-phenylamino]-methyl}-1-methyl-1 H-benzimidazol acid ethyl ester and the salts thereof	Jun 14, 2023 (Expired)	Boehringer Ingelheim
Pradaxa	US6087380 (Pediatric)	Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions	Jun 28, 2022 (Expired)	Boehringer Ingelheim
Pradaxa	US6087380	Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions	Dec 28, 2021 (Expired)	Boehringer Ingelheim
Pradaxa	US6087380	Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions	Feb 18, 2018 (Expired)	Boehringer Ingelheim

Add above patents to watchlist

Dabigatran Etexilate Mesylate's Family Patents

Full family tree

Dabigatran Etexilate Mesylate Generic API Manufacturers

Several generic applications have been filed for Dabigatran Etexilate Mesylate. The first generic version for Dabigatran Etexilate Mesylate was by Alkem Laboratories Ltd and was approved on Mar 11, 2020. And the latest generic version is by Aurobindo Pharma Ltd and was approved on May 14, 2025.

Given below is the list of companies who have filed for Dabigatran Etexilate Mesylate generic, along with the locations of their manufacturing plants worldwide.